Regulation of Pathogen Sequencing Reporting Systems in China

1. Introduction

China regulates pathogen sequencing and reporting through a combination of infectious disease control legislation, public health surveillance rules, biosafety requirements, human genetic resource regulations, data protection laws, and administrative reporting mechanisms. These rules govern how laboratories identify pathogens, sequence their genomes, report unusual findings, share surveillance information, and protect sensitive biological and genomic data.

Pathogen sequencing is important for detecting emerging infectious diseases, identifying mutations, tracing transmission patterns, monitoring antimicrobial resistance, and supporting outbreak investigations. However, sequencing data can also reveal sensitive information about individuals, populations, biological materials, and potentially dangerous pathogens. Chinese law therefore seeks to coordinate public health surveillance with biosafety, data security, and governmental supervision.

The regulatory framework does not consist of one comprehensive statute devoted exclusively to pathogen sequencing reporting. Instead, several legal instruments apply according to the pathogen involved, the purpose of sequencing, the institution conducting the work, and the nature of the resulting data.

2. Principal Legal Framework

A. Law on the Prevention and Treatment of Infectious Diseases

China's Law on the Prevention and Treatment of Infectious Diseases is a central legal foundation for infectious disease surveillance and reporting. It establishes duties concerning the detection, notification, investigation, and control of legally classified infectious diseases.

Medical institutions, disease prevention and control institutions, and relevant personnel must comply with applicable infectious disease reporting requirements. Where sequencing identifies a pathogen associated with a reportable disease, the laboratory finding may trigger or support these obligations.

The legal significance is that sequencing does not replace statutory disease reporting. A laboratory cannot necessarily satisfy its reporting obligations merely by uploading sequence data to a research database. The appropriate disease surveillance and public health authorities must receive the notifications required by law.

The revised law adopted in 2025 strengthens the importance of examining the current statutory framework rather than relying exclusively on older outbreak-era practices. The precise reporting duty depends on the disease classification, the applicable implementing rules, and the circumstances of detection.

B. Biosecurity Law of the People's Republic of China

The Biosecurity Law, effective from 15 April 2021, provides a broader framework for managing biological risks.

Its relevance to pathogen sequencing includes:

Surveillance and early warning of major infectious diseases and emerging biological threats.

Oversight of pathogenic microorganisms and potentially hazardous biological activities.

Prevention and control of risks associated with biotechnology research and laboratory operations.

Coordination among public health, scientific research, and other competent authorities.

Protection of national biosecurity interests in the handling and sharing of biological information.

Sequencing laboratories must therefore consider not only whether a result is medically significant but also whether the organism, research activity, or information creates a regulated biological risk.

The law establishes the general biosecurity framework; specific laboratory approvals, biosafety classifications, and reporting procedures are determined through related legislation and implementing regulations.

C. Regulations on Pathogenic Microorganism Laboratories

The Biosecurity Law's provisions on pathogenic microorganism laboratories establish requirements concerning laboratory establishment, classification, safe handling of biological materials, and reporting of biosafety incidents.

Articles 43–50 are particularly relevant. They regulate activities involving highly pathogenic or suspected highly pathogenic microorganisms, laboratory approval and filing, appropriate biosafety protection levels, and emergency response to incidents such as the loss or release of dangerous microorganisms.

NPC

+1

For sequencing laboratories, these provisions matter when sample handling or associated experimental procedures fall within the regulated activities. A sequencing result may also require escalation if it reveals an unexpected biological hazard or is associated with a laboratory safety incident.

D. Regulations on Data Security and Human Genetic Resources

Three additional laws are important:

Personal Information Protection Law (2021): applies where pathogen sequencing records contain identifiable patient information or other personal data.

Data Security Law (2021): establishes obligations concerning data classification, risk management, and the security of important data.

Regulations on the Administration of Human Genetic Resources (2019, as amended): may apply when sequencing involves human genetic resources or information derived from human biological materials.

The Human Genetic Resources framework is particularly important for international research collaborations. Article 57 of the Biosecurity Law addresses the provision of Chinese human genetic resource information to overseas organisations or individuals and requires advance reporting with a duplicate of the information, subject to the applicable legal framework.

NPC

+1

Important distinction: pathogen genome sequences and human genomic information are not legally identical. A sequence obtained from a pathogen does not automatically become human genetic resource information. However, associated patient genomic data, identifiable clinical records, and biological materials may trigger additional regulatory obligations.

3. How Pathogen Sequencing Reporting Works

The system can be understood as a series of connected legal and institutional responsibilities.

1. Pathogen detection and sequencing

Hospital, diagnostic laboratory, research institution or surveillance centre

2. Validation and risk assessment

Assess pathogen identity, unusual variants, outbreak signals and laboratory risks

3. Statutory notification

Report notifiable disease cases and qualifying emergencies through the applicable official channels

4. Public health assessment and response

Disease control authorities analyse surveillance information and coordinate warnings or interventions

The sequence above is an explanatory model, not a claim that every laboratory follows one identical national sequencing workflow. Reporting routes and deadlines depend on the applicable disease, institution, and emergency classification.

A particularly significant recent development is the revised Law on the Prevention and Control of Infectious Diseases, effective from 1 September 2025. The revised law specifies online direct-reporting deadlines of two hours for specified Category A cases, emerging infectious diseases, and unexplained infectious diseases, and 24 hours for specified Category B and Category C cases. These are disease-reporting deadlines, not a universal deadline for uploading every genomic sequence.

State Council of China

+1

China also issued trial regulations on infectious disease outbreak early warnings in 2025, strengthening the collection and analysis of surveillance data, risk assessment, and early-warning procedures.

State Council of China

4. Relevant Cases and Their Legal Significance

There appears to be no widely established, reported Chinese judicial decision directly determining the legality of a pathogen genome-sequencing reporting system as a distinct legal subject. Nevertheless, several cases and incidents provide useful guidance on related questions of reporting, research governance, and regulatory responsibility.

A. Li Wenliang incident (2019–2020)

Dr. Li Wenliang, a Wuhan ophthalmologist, raised concerns about a cluster of unusual pneumonia cases in December 2019. Police reprimanded him for allegedly spreading rumours; the Wuhan Public Security Bureau later revoked the reprimand.

Legal significance: The incident illustrates the importance of distinguishing good-faith warnings about emerging infectious diseases from legally actionable misinformation. It also demonstrates why effective surveillance systems need timely escalation procedures and clear reporting responsibilities.

Limitation: This was an administrative and disciplinary incident, not a judicial ruling specifically concerning pathogen sequencing or genomic data reporting.

B. He Jiankui criminal case (2019)

Chinese scientist He Jiankui was convicted in 2019 for illegally practising medicine in connection with gene-edited babies. The Shenzhen court imposed a three-year prison sentence and a fine.

Legal significance: The case demonstrates that biotechnology research remains subject to legal and professional restrictions even where researchers invoke scientific innovation. In the sequencing context, it supports the broader principle that research involving human genetic material must comply with applicable ethical, licensing, and regulatory requirements.

Limitation: The case concerned human gene-editing research, not a failure to report pathogen sequences. It should therefore be treated as an analogous biotechnology-governance case rather than direct precedent.

C. COVID-19 genomic surveillance and reporting

The early COVID-19 outbreak generated major questions about the timing of outbreak notifications, laboratory findings, scientific communication, and sharing of viral genomic information.

The legal framework now places infectious disease monitoring, reporting, and early warning within a more developed statutory structure, particularly through the Biosecurity Law and the revised infectious disease legislation.

Legal significance: The experience illustrates why a genomic surveillance system must distinguish between notifying public health authorities, publishing research findings, and sharing sequence data with domestic or international partners. These are related but legally separate activities.

Limitation: The public controversies surrounding early COVID-19 reporting should not be described as judicial precedents unless a specific court judgment addressing the relevant legal issue can be identified.

5. Legal Liability for Non-Compliance

Depending on the conduct and applicable provision, violations may result in:

Administrative penalties for failures to comply with infectious disease reporting or laboratory safety requirements.

Corrective orders and sanctions for unlawful handling of pathogenic microorganisms.

Data protection or data security liability for unlawful disclosure, processing, or transfer of protected information.

Civil liability where unlawful conduct causes legally recognised harm.

Criminal liability where the facts satisfy a specific criminal offence.

Not every delay in sequencing, failure to publish a genome, or disagreement over scientific interpretation constitutes an offence. Liability depends on the precise statutory duty, the responsible person or institution, the circumstances, and the applicable enforcement provision.

6. Conclusion

China's pathogen sequencing reporting system is governed by an interconnected framework of infectious disease legislation, biosecurity regulation, laboratory oversight, and data protection rules. Its central legal principle is that genomic surveillance must support timely public health detection without bypassing statutory reporting channels or compromising regulated biological and personal information.

The revised infectious disease law effective from 1 September 2025 reinforces the importance of rapid notification, while the Biosecurity Law provides the broader framework for biological risk surveillance and laboratory safety. The principal difficulty in applying these rules is determining which reporting obligation applies to a particular sequencing result and whether additional controls arise from the pathogen, the human material involved, or the intended transfer of data.

For legal research, the most defensible approach is to distinguish binding statutory requirements, administrative implementation, and analogous judicial cases rather than treating every outbreak controversy or biotechnology prosecution as direct case law on pathogen sequencing.